Bernard A. Fox, Co- founder, President, and CEO of UbiVac, shared Patrick Hwu’s, President and CEO at Moffitt Cancer Center, shared a post on LinkedIn:
“I am delighted to announce that my friend and colleague of more than 30 years, Dr. Walter Urba, has joined UbiVac’s Scientific Advisory Board to help guide the clinical development of the world’s first Dark Matter Cancer Vaccine towards potential accelerated FDA approval.
‘I am excited to join UbiVac’s Scientific Advisory Board at a time when the field is increasingly recognizing the importance of non-canonical tumor antigens as targets for immunotherapy.’
said Dr. Urba.
‘UbiVac’s platform is uniquely positioned to exploit this emerging biology by combining broad antigenic coverage with endogenous immune stimulation in an off-the-shelf therapeutic approach.’
Walter J. Urba, MD, is an internationally recognized leader in cancer immunotherapy and translational oncology. He previously served as Chief Medical Officer of Providence Cancer Institute and Founding Director of the Cancer Research Program at the Earle A. Chiles Research Institute, where he helped establish one of the nation’s leading immuno-oncology research and clinical trial programs. Dr. Urba has played a major role in advancing cytokine therapy, cancer vaccines, adoptive cellular therapy, and immune checkpoint inhibition.
Dr. Urba also knows the detailed science behind UbiVac’s vaccine technology. He was the Director when Dr. Hong-Ming Hu working at the Institute invented the technology and when UbiVac spun out of Providence. Dr. Urba was also the Principal Investigator on the first two National Cancer Institute (NCI) -funded clinical trials that explored UbiVac’s vaccine strategy – first in a personalized tumor-specific platform, and subsequently in the current off-the-shelf format.”
Other articles about UbiVac on OncoDaily.